SK Plasma

Albumin products supplied as SK Albumin 20% and 5% injections.

Immunoglobulin products supplied as Livgamma S&N 10% and 5% injections, alongside other immunoglobulins such as Hepabulin S&N for IV injection.

Coagulation-related products supplied as SK Antithrombin III 500 units and ETV 250 units injections.

KGMP plant on a site of about 30,000 m² in Andong, Gyeongsangbuk-do, completed in 2016, with plasma fractionation and purification facilities, remote monitoring (SCADA) and automated energy management.

Joint venture for SK Plasma's Indonesian plant, building an albumin and immunoglobulin facility with annual capacity for 600,000 litres of plasma on a site of about 49,000 m² in the Karawang industrial complex.

Signed a memorandum of understanding with Indonesia's sovereign wealth fund Danantara Indonesia on investment in blood-product manufacturing infrastructure for its local joint venture, SK Plasma Core Indonesia.

Signed a technology transfer and licence agreement worth a total of EUR 65 million (about KRW 110 billion after tax) with ProTurk, a joint venture set up with the Turkish Red Crescent to build a plasma fractionation plant.

Broke ground on a plasma fractionation plant with annual capacity for 600,000 litres of plasma in Çubuk, Ankara, Türkiye, for albumin, immunoglobulin and factor VIII products; SK Plasma holds a 15% stake and handles technology transfer, quality management and local staff training.